

# PATIENT INFORMATION

**NAME:** Sample 5 S550  
**ACC #:** PHI00000  
**DOB:** 1/1/1900  
**SEX:** M

# SPECIMEN DETAILS

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 9/17/2016

# ORDERED BY

Doctor, Doctor

# Gene Panel

# Test Details

Gene	Genotype	Phenotype	Clinical Consequences
COMT	Val158Met AG	Intermediate COMT Activity	Consistent with a reduced catechol O-methyltransferase (COMT) function.
CYP1A2	*1A/*1F	Normal Metabolizer - Higher Inducibility	Consistent with a typical CYP1A2 activity in absence of inducing substances. Rapid Metabolism occurs in presence of inducers such as barbiturates, cruciferous vegetables, carbamazepine, rifampin and smoking.
CYP2C19	*1/*17	Rapid Metabolizer	Consistent with a significant increase in CYP2C19 activity. Potential risk for side effects or loss of efficacy with drug substrates.
CYP2C9	*1/*3	Intermediate Metabolizer	Consistent with a moderate deficiency in CYP2C9 activity. Potential risk for side effects or loss of efficacy with drug substrates.
CYP2D6	*1/*3	Normal Metabolizer	Consistent with a typical CYP2D6 activity. This test did not identify risks for side effects or loss of efficacy with drug substrates.
CYP3A4	*1/*1	Normal Metabolizer	Consistent with a typical CYP3A4 activity. Caution is advised when prescribing narrow therapeutic index drugs. Alternative drugs or dose adjustment may be required if CYP3A inhibitors or inducers are co-prescribed.
CYP3A5	*3/*3	Poor Metabolizer	Consistent with a poor CYP3A5 activity. This phenotype is the most common in the general population. Caution is advised when prescribing narrow therapeutic index drugs. Alternative drugs or dose adjustment may be required if CYP3A inhibitors or inducers are co-prescribed.
Factor II Factor V Leiden	20210G>A GG 1691G>A GG	No Increased Risk of Thrombosis	The patient's risk of thrombosis is not increased (average risk of clotting is about 1 in 1000 for anyone in a year). However, because this test cannot find all of the inherited reasons for abnormal clotting, other factors may affect this risk assessment.
LPA	rs10455872 A/A rs3798220 T/T	No increased risk of cardiovascular disease	The patient is a non carrier of the risk alleles in LPA gene for both the variants (rs3798220 and rs10455872).
MTHFR	677C>T CC	Normal MTHFR Activity	The patient does not carry the MTHFR C677T mutation (wild-type) and the patient's MTHFR activity is normal. This is not associated with an increased risk of hyperhomocysteinemia.
MTHFR	1298A>C AC 677C>T CC	No Increased Risk of Hyperhomocysteinemia	The patient's slightly reduced MTHFR activity is not a risk factor for hyperhomocysteinemia. Unless other risk factors are present, the patient is not expected to have an increased risk for venous thromboembolism (VTE).
OPRM1	A118G AG	Altered OPRM1 Function	Consistent with a reduced OPRM1 receptor signaling efficiency induced by exogenous opioids. This is associated with a possible reduced analgesia following standard opioid doses and a favorable response to naltrexone.
SLC6A4	463T>G A/A	Homozygous for A Allele	
SLCO1B1	521T>C TT	Normal Function	Consistent with a typical SLCO1B1 transporter function. The patient's risk for statin-induced myopathy is not increased.
VKORC1	-1639G>A G/G	Low Warfarin Sensitivity	VKORC1 is the site of action of warfarin. The patient may require an increase in warfarin dose.

**Alleles Tested:** COMT Val158Met; CYP1A2 \*1F; CYP2C19 \*2, \*3, \*4, \*4B, \*5, \*6, \*7, \*8, \*9, \*10, \*17; CYP2C9 \*2, \*3; CYP2D6 \*2, \*3, \*4, \*4M, \*6, \*7, \*8, \*9, \*10, \*12, \*17, \*29, \*35, \*41, \*5 (gene deletion), XN (gene duplication); CYP3A4 \*1B, \*22; CYP3A5 \*3, \*3C, \*6, \*7; Factor II 20210G>A; Factor V Leiden 1691G>A; LPA rs3798220, rs10455872; MTHFR 1298A>C, 677C>T; OPRM1 A118G; SLC6A4 463T>G; SLCO1B1 521T>C; VKORC1 -1639G>A

**PATIENT INFORMATION**

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

**SPECIMEN DETAILS**

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

**ORDERED BY**

Doctor, Doctor

## Report Overview

1. Test Results
2. Report Overview
3. Risk Management
4. Current Patient Medications
5. Potentially Impacted Medications
6. Dosing Guidance
7. Monographs
8. Patient Card



A medication has potentially reduced efficacy, increased toxicity or the patient has an increased risk for the indicated condition.

**ACTIONABLE**

Guidelines exist for adjusting dosage, increased vigilance or the patient has a moderate risk for the indicated condition.



The medication can be prescribed according to standard regimens or the patient's risk for the indicated condition is not increased.

**INFORMATIVE**

Recommendations based upon publications by international pharmacogenetic expert groups, consortia or regulatory bodies (CPIC, DPWG, FDA, EMA). Recommendations are suitable for implementation in a clinical setting. Guidelines may change as knowledge arises.

There are insufficient or contradictory findings documenting the impact of a given genetic polymorphism or drug interaction. Recommendations are informative and implementation in a clinical setting is optional.

**PATIENT INFORMATION**

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

**SPECIMEN DETAILS**

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

**ORDERED BY**

Doctor, Doctor

## Risk Management



### Hyperhomocysteinemia - Depression

#### No Increased Risk of Hyperhomocysteinemia

The patient does not carry the MTHFR C677T variant. MTHFR enzyme activity is normal.

Patients diagnosed with depression often have low folate levels and homocysteine is a highly sensitive marker of folate status. Functional folate deficiency is indicated by elevated homocysteine. With a normal MTHFR activity, this patient can process folate normally and is unlikely to have elevated plasma levels of homocysteine.

Patients diagnosed with depression: as lower folate levels are associated with poorer antidepressant response, and baseline levels of folate within the normal range predict antidepressant response, testing for homocysteine levels and serum folate levels may be informative for this patient before prescribing methylfolate as an antidepressant-augmenting agent.



### Thrombophilia

#### No Increased Risk of Thrombosis

The patient does not carry the Factor V Leiden G1691A mutation or Factor II G20210A mutation (wild-type).

The patient's risk of thrombosis is not increased (average risk of clotting is about 1 in 1000 for anyone in a year). However, because this test cannot find all of the inherited reasons for abnormal clotting, other factors may affect this risk assessment.

Unless other genetic and/or circumstantial risk factors are present (e.g., smoking or obesity...), estrogen-containing contraceptive and hormone replacement therapy can be used by the patient.



### Hyperhomocysteinemia - Thrombosis

#### No Increased Risk of Hyperhomocysteinemia

The patient carries one MTHFR A1298C mutation (heterozygous). MTHFR enzyme activity is reduced (80% of normal activity).

The patient's slightly reduced MTHFR activity is not a risk factor for hyperhomocysteinemia. Unless other risk factors are present, the patient is not expected to have an increased risk for venous thromboembolism (VTE).

The patient's MTHFR activity is slightly reduced.



### Hyperlipidemia/Atherosclerotic Cardiovascular Disease

#### No increased risk of cardiovascular disease

The patient is a non carrier of the risk alleles in LPA gene for both the variants (rs3798220 and rs10455872).

The patient's genotype is associated with normal lipoprotein levels. The patient has no increased risk of atherosclerosis and cardiovascular disease as compared to the general population unless other risk factors are present.

No action is needed for this patient unless other genetic and non genetic risk factors (e.g. high blood pressure, smoking, diabetes, obesity, high blood cholesterol and excessive alcohol use) are present.











**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

Doctor, Doctor

## Current Patient Medications

Plavix, Starlix, Tamoxifen, Lipitor, Codeine, Ritalin, Amphetamine, Zonegran, Paxil, Flomax

	<b>Plavix</b> <i>Clopidogrel</i>	<b>Increased Response to Clopidogrel (CYP2C19: Rapid Metabolizer)</b> Clopidogrel can be prescribed at standard label-recommended dosage. Individuals with the *17 allele may have an increased risk of bleeding while taking clopidogrel.	<b>ACTIONABLE</b>
	<b>Ritalin</b> <i>Methylphenidate</i>	<b>Decreased Response to Methylphenidate (COMT: Intermediate COMT Activity)</b> The patient's genotype result predicts a less optimal response to methylphenidate. Dosage should be individualized according to the needs and response of the patient. Therapy should be initiated in small doses, with gradual weekly increments.	<b>INFORMATIVE</b>
	<b>Amphetamine</b> <i>Adderall</i>	<b>Good Response to Amphetamine salts (COMT: Intermediate COMT Activity)</b> The patient's genotype result predicts a favorable response to amphetamine stimulants. Amphetamines should be administered at the lowest effective dose, and dosage should be individually adjusted.	<b>INFORMATIVE</b>
	<b>Codeine</b> <i>Codeine; Fioricet with Codeine</i>	<b>Normal Response to Codeine (CYP2D6: Normal Metabolizer)</b> Codeine can be prescribed at standard label-recommended dosage and administration.	<b>ACTIONABLE</b>
	<b>Flomax</b> <i>Tamsulosin</i>	<b>Normal Response to Tamsulosin (CYP2D6: Normal Metabolizer)</b> Tamsulosin can be prescribed at standard label-recommended dosage and administration.	<b>ACTIONABLE</b>
	<b>Lipitor</b> <i>Atorvastatin</i>	<b>Normal Myopathy Risk (SLCO1B1: Normal Function)</b> Atorvastatin plasma concentrations are not expected to increase, and unless other genetic or circumstantial risk factors are present, atorvastatin can be prescribed at standard FDA-recommended starting doses and adjusted based on disease-specific guidelines. (Other myopathy predisposing factors include advanced age (≥65), uncontrolled hypothyroidism, renal impairment, high statin dose, comedications, and female gender.)	<b>INFORMATIVE</b>
	<b>Lipitor</b> <i>Atorvastatin</i>	<b>Normal Response to Atorvastatin (CYP3A4: Normal Metabolizer)</b> The genotype result indicates that the patient does not carry the CYP3A4*22 allele (this allele is associated with a decreased CYP3A4 enzyme activity). The patient is expected to achieve an optimal lipid control goal with standard atorvastatin dose requirements.	<b>INFORMATIVE</b>
	<b>Paxil</b> <i>Paroxetine</i>	<b>Normal Sensitivity to Paroxetine (CYP2D6: Normal Metabolizer)</b> Paroxetine can be prescribed at standard label-recommended dosage and administration. Careful titration is recommended until a favorable response is achieved.	<b>ACTIONABLE</b>
	<b>Starlix</b> <i>Nateglinide</i>	<b>Normal Sensitivity to Nateglinide (SLCO1B1: Normal Function)</b> The patient carries two copies of SLCO1B1 rs4149056 T allele, which is associated with normal transporter function. Nateglinide can be prescribed at label-recommended standard dosage and administration.	<b>INFORMATIVE</b>
	<b>Starlix</b> <i>Nateglinide</i>	<b>Normal Sensitivity to Nateglinide (CYP2C9: Intermediate Metabolizer)</b> The patient's genotype predicts a normal exposure to nateglinide, and this drug can be prescribed at label-recommended dosage and administration.	<b>INFORMATIVE</b>

**PATIENT INFORMATION**

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

**SPECIMEN DETAILS**

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

**ORDERED BY**

Doctor, Doctor

**Zonegran**

*Zonisamide*

**Normal Sensitivity to Zonisamide (CYP2C19: Rapid Metabolizer)****INFORMATIVE**

CYP2C19 is partly involved in the metabolism of zonisamide, and this drug can be prescribed at standard label-recommended dosage and administration.

**Medications outside the scope of the report:** Tamoxifen



## PATIENT INFORMATION

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

## SPECIMEN DETAILS

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

## ORDERED BY

Doctor, Doctor

## Potentially Impacted Medications

CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
Anticancer Agents	Antifolates	Methotrexate (Trexall)		
	Angiotensin II Receptor Antagonists	Azilsartan (Edarbi, Edarbyclor) Candesartan (Atacand) Eprosartan (Teveten) Irbesartan (Avapro) Losartan (Cozaar, Hyzaar) Olmesartan (Benicar) Telmisartan (Micardis) Valsartan (Diovan, Entresto)		
	Antianginal Agents	Ranolazine (Ranexa)		
	Antiarrhythmics	Flecainide (Tambocor) Mexiletine (Mexitol) Propafenone (Rythmol)		
Cardiovascular	Anticoagulants	Apixaban (Eliquis) Dabigatran Etexilate (Pradaxa) Edoxaban (Savaysa) Fondaparinux (Arixtra) Rivaroxaban (Xarelto)	Warfarin (Coumadin)	
	Antiplatelets	Prasugrel (Effient) Ticagrelor (Brilinta) Vorapaxar (Zontivity)	Clopidogrel (Plavix)	
	Beta Blockers	Atenolol (Tenormin) Bisoprolol (Zebeta) Carvedilol (Coreg) Labetalol (Normodyne, Trandate) Metoprolol (Lopressor) Nebivolol (Bystolic) Propranolol (Inderal) Timolol (Timoptic)		
	Diuretics	Torsemide (Demadex)		
	Statins	Atorvastatin (Lipitor) Lovastatin (Mevacor, Altoprev, Advicor) Pitavastatin (Livalo) Pravastatin (Pravachol) Rosuvastatin (Crestor) Simvastatin (Zocor)	Fluvastatin (Lescol)	
Diabetes	Meglitinides	Nateglinide (Starlix) Repaglinide (Prandin, Prandimet)		
	Sulfonylureas	Chlorpropamide (Diabenese) Glimepiride (Amaryl) Glipizide (Glucotrol) Glyburide (Micronase) Tolbutamide (Orinase)		



## PATIENT INFORMATION

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

## SPECIMEN DETAILS

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

## ORDERED BY

Doctor, Doctor

CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
Gastrointestinal	Antiemetics	Dolasetron (Anzemet) Metoclopramide (Reglan) Ondansetron (Zofran, Zuplenz) Palonosetron (Aloxi)		
	Proton Pump Inhibitors	Rabeprazole (Aciphex)	Dexlansoprazole (Dexilant, Kapidex) Esomeprazole (Nexium) Lansoprazole (Prevacid) Omeprazole (Prilosec) Pantoprazole (Protonix)	
Infections	Antifungals		Voriconazole (Vfend)	
	Antimalarials	Proguanil (Malarone)		
Pain	Fibromyalgia Agents	Milnacipran (Savella)		
	Muscle Relaxants	Cyclobenzaprine (Flexeril, Amrix) Metaxalone (Skelaxin) Methocarbamol (Robaxin)	Carisoprodol (Soma) Tizanidine (Zanaflex)	
	NSAIDs	Ibuprofen (Advil, Motrin) Ketoprofen (Orudis) Ketorolac (Toradol) Nabumetone (Relafen) Naproxen (Aleve) Sulindac (Clinoril)	Celecoxib (Celebrex) Diclofenac (Voltaren) Flurbiprofen (Ansaid) Indomethacin (Indocin) Meloxicam (Mobic) Piroxicam (Feldene)	
	Opioids	Alfentanil (Alfenta) Buprenorphine (Butrans, Buprenex) Codeine (Codeine; Fioricet with Codeine) Dihydrocodeine (Synalgos-DC) Hydromorphone (Dilaudid, Exalgo) Levorphanol (Levo Dromoran) Meperidine (Demerol) Morphine (MS Contin) Oxycodone (Percocet, Oxycontin) Oxymorphone (Opana, Numorphan) Sufentanil (Sufenta) Tapentadol (Nucynta) Tramadol (Ultram)	Fentanyl (Actiq) Hydrocodone (Vicodin)	
	Antiaddictives	Naltrexone (Vivitrol, Contrave)		
	Anti-ADHD Agents	Amphetamine (Adderall) Atomoxetine (Strattera) Clonidine (Kapvay) Dextroamphetamine (Dexedrine) Guanfacine (Intuniv) Lisdexamfetamine (Vyvanse)	Dexmethylphenidate (Focalin) Methylphenidate (Ritalin)	



## PATIENT INFORMATION

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

## SPECIMEN DETAILS

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

## ORDERED BY

Doctor, Doctor

## CATEGORY

## DRUG CLASS

## STANDARD PRECAUTIONS

## USE WITH CAUTION

## CONSIDER ALTERNATIVES

## Anticonvulsants

Brivaracetam (Briviact)  
Carbamazepine (Tegretol, Carbatrol, Epitol)  
Eslicarbazepine (Aptiom)  
Ethosuximide (Zarontin)  
Ezogabine (Potiga)  
Felbamate (Felbatol)  
Gabapentin (Neurontin)  
Lacosamide (Vimpat)  
Lamotrigine (Lamictal)  
Levetiracetam (Keppra)  
Oxcarbazepine (Trileptal, Oxtellar XR)  
Perampanel (Fycompa)  
Phenobarbital (Luminal)  
Pregabalin (Lyrica)  
Primidone (Mysoline)  
Rufinamide (Banzel)  
Tiagabine (Gabitril)  
Topiramate (Topamax)  
Valproic Acid (Depakote, Depakene)  
Vigabatrin (Sabril)  
Zonisamide (Zonegran)

Fosphenytoin (Cerebyx)  
Phenytoin (Dilantin)

## Antidementia Agents

Donepezil (Aricept)  
Galantamine (Razadyne)  
Memantine (Namenda)

## Psychotropic

## Antidepressants

Amoxapine (Amoxapine)  
Desipramine (Norpramin)  
Desvenlafaxine (Pristiq)  
Duloxetine (Cymbalta)  
Fluoxetine (Prozac, Sarafem)  
Fluvoxamine (Luvox)  
Levomilnacipran (Fetzima)  
Maprotiline (Ludiomil)  
Mirtazapine (Remeron)  
Nefazodone (Serzone)  
Nortriptyline (Pamelor)  
Paroxetine (Paxil, Brisdelle)  
Protriptyline (Vivactil)  
Trazodone (Oleptro)  
Venlafaxine (Effexor)  
Vilazodone (Viibryd)  
Vortioxetine (Trintellix)

Sertraline (Zoloft)

Amitriptyline (Elavil)  
Citalopram (Celexa)  
Clomipramine (Anafranil)  
Doxepin (Silenor)  
Escitalopram (Lexapro)  
Imipramine (Tofranil)  
Trimipramine (Surmontil)





PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
<b>NAME:</b> Sample 5 S550	<b>SPECIMEN TYPE:</b> Buccal	Doctor, Doctor
<b>ACC #:</b> S550	<b>COLLECTION DATE:</b> 9/7/2016	PHI TEST
<b>DOB:</b> 1/1/1900	<b>RECEIVED DATE:</b> 9/8/2016	
<b>SEX:</b> M	<b>REPORT DATE:</b> 2/6/2017	

CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
	Antipsychotics	Aripiprazole (Abilify) Asenapine (Saphris) Brexipiprazole (Rexulti) Chlorpromazine (Thorazine) Fluphenazine (Prolixin) Haloperidol (Haldol) Iloperidone (Fanapt) Loxapine (Loxitane, Adasuve) Lurasidone (Latuda) Paliperidone (Invega) Perphenazine (Trilafon) Pimavanserin (Nuplazid) Pimozide (Orap) Quetiapine (Seroquel) Risperidone (Risperdal) Thioridazine (Mellaril) Thiothixene (Navane) Trifluoperazine (Stelazine) Ziprasidone (Geodon)	Clozapine (Clozaril) Olanzapine (Zyprexa) Tetrabenazine (Xenazine)	
	Benzodiazepines	Alprazolam (Xanax) Clobazam (Onfi) Clonazepam (Klonopin)	Diazepam (Valium)	
	Other Neurological Agents	Dextromethorphan / Quinidine (Nuedexta) Flibanserin (Addyi)		
Rheumatology	Anti-Gout Agents	Colchicine (Mitigare) Febuxostat (Uloric) Lesinurad (Zurampic)		
	Immunomodulators	Apremilast (Otezla) Leflunomide (Arava) Tofacitinib (Xeljanz)		
Transplantation	Immunosupressants	Tacrolimus (Prograf)		
Urologicals	5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia	Dutasteride (Avodart) Finasteride (Proscar)		
	Alpha-Blockers for Benign Prostatic Hyperplasia	Alfuzosin (UroXatral) Doxazosin (Cardura) Silodosin (Rapaflo) Tamsulosin (Flomax) Terazosin (Hytrin)		
	Antispasmodics for Overactive Bladder	Darifenacin (Enablex) Fesoterodine (Toviaz) Mirabegron (Myrbetriq) Oxybutynin (Ditropan) Solifenacin (Vesicare) Tolterodine (Detrol) Tropium (Sanctura)		
	Phosphodiesterase Inhibitors for Erectile Dysfunction	Avanafil (Stendra) Sildenafil (Viagra) Tadalafil (Cialis) Vardenafil (Levitra)		

#### PATIENT INFORMATION

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M











#### SPECIMEN DETAILS

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

#### ORDERED BY

Doctor, Doctor

## Dosing Guidance

 <b>Amitriptyline</b> <i>Elavil</i>	<b>Increased Sensitivity to Amitriptyline (CYP2C19: Rapid Metabolizer)</b> Consider an alternative drug, or consider prescribing amitriptyline at standard dose and monitor the plasma concentrations of amitriptyline and nortriptyline to guide dose adjustments.	<b>INFORMATIVE</b>
 <b>Citalopram</b> <i>Celexa</i>	<b>Insufficient Response to Citalopram (CYP2C19: Rapid Metabolizer)</b> At standard label-recommended dosage, citalopram plasma concentrations levels are expected to be low which may result in a loss of efficacy. Consider an alternative medication. If citalopram is warranted, consider increasing the dose to a maximum of 150% and titrate based on the clinical response and tolerability.	<b>ACTIONABLE</b>
 <b>Clomipramine</b> <i>Anafranil</i>	<b>Increased Sensitivity to Clomipramine (CYP2C19: Rapid Metabolizer)</b> Consider an alternative drug, or consider prescribing clomipramine at standard dose and monitor the plasma concentrations of clomipramine and desmethyl-clomipramine to guide dose adjustments.	<b>INFORMATIVE</b>
 <b>Doxepin</b> <i>Silenor</i>	<b>Increased Sensitivity to Doxepin (CYP2C19: Rapid Metabolizer)</b> Consider an alternative drug, or consider prescribing doxepin at standard dose and monitor the plasma concentrations of doxepin and desmethyl-doxepin to guide dose adjustments.	<b>INFORMATIVE</b>
 <b>Escitalopram</b> <i>Lexapro</i>	<b>Insufficient Response to Escitalopram (CYP2C19: Rapid Metabolizer)</b> At standard label-recommended dosage, escitalopram plasma concentrations levels are expected to be low which may result in a loss of efficacy. Consider an alternative medication. If escitalopram is warranted, consider increasing the dose to a maximum of 150% and titrate based on the clinical response and tolerability.	<b>ACTIONABLE</b>
 <b>Imipramine</b> <i>Tofranil</i>	<b>Increased Sensitivity to Imipramine (CYP2C19: Rapid Metabolizer)</b> Consider an alternative drug, or consider prescribing imipramine at the standard dose and monitor the plasma concentrations of imipramine and desipramine to guide dose adjustments.	<b>INFORMATIVE</b>
 <b>Trimipramine</b> <i>Surmontil</i>	<b>Increased Sensitivity to Trimipramine (CYP2C19: Rapid Metabolizer)</b> Consider an alternative drug, or consider prescribing trimipramine at standard dose and monitor the plasma concentrations of trimipramine and desmethyl-trimipramine to guide dose adjustments.	<b>INFORMATIVE</b>
 <b>Carisoprodol</b> <i>Soma</i>	<b>Altered Sensitivity to Carisoprodol (CYP2C19: Rapid Metabolizer)</b> There is insufficient data to allow calculation of dose adjustment. If carisoprodol is prescribed, it is recommended to use a lower dose, and to carefully monitor the patient for side effects.	<b>INFORMATIVE</b>
 <b>Celecoxib</b> <i>Celebrex</i>	<b>Possible Sensitivity to Celecoxib (CYP2C9: Intermediate Metabolizer)</b> Celecoxib can be prescribed at standard label-recommended dosage and administration. Evaluate response the first week and be alert to gastrointestinal adverse events.	<b>INFORMATIVE</b>
 <b>Clopidogrel</b> <i>Plavix</i>	<b>Increased Response to Clopidogrel (CYP2C19: Rapid Metabolizer)</b> Clopidogrel can be prescribed at standard label-recommended dosage. Individuals with the *17 allele may have an increased risk of bleeding while taking clopidogrel.	<b>ACTIONABLE</b>



## PATIENT INFORMATION

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

## SPECIMEN DETAILS

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

## ORDERED BY

Doctor, Doctor

**Clozapine**  
*Clozaril***Non-Response to Clozapine (CYP1A2: Normal Metabolizer - Higher Inducibility)**

INFORMATIVE

Smokers have a high risk for non-response at standard doses and may require higher doses. There is an association between high clozapine doses and the risk of seizures, and therefore careful monitoring is recommended during dosing adjustment. Smoking cessation will increase plasma drug levels, leading to adverse events. Therefore, therapeutic drug monitoring accompanied by dose reduction is recommended in patients who have quit smoking.

**Dexlansoprazole**  
*Dexilant, Kapidex***Insufficient Response to Dexlansoprazole (CYP2C19: Rapid Metabolizer)**

INFORMATIVE

- Helicobacter pylori eradication: increase dose by 200% and be alert to insufficient response.
- Other: be extra alert to insufficient response and consider dose increase of 200%.

**Dexmethylphenidate**  
*Focalin***Decreased Response to Dexmethylphenidate (COMT: Intermediate COMT Activity)**

INFORMATIVE

The patient's genotype result predicts a less optimal response to dexmethylphenidate. Dosage should be individualized according to the needs and response of the patient. Therapy should be initiated in small doses, with gradual weekly increments.

**Diazepam**  
*Valium***Possible Altered Sensitivity to Diazepam (CYP2C19: Rapid Metabolizer)**

INFORMATIVE

CYP2C19 rapid and ultra-rapid metabolizers metabolize diazepam and nordiazepam more rapidly than normal metabolizers. However, there is insufficient data to allow calculation of dose adjustment when diazepam is prescribed. Monitor the patient's response and adjust the dose accordingly.

**Diclofenac**  
*Voltaren***Possible Sensitivity to Diclofenac (CYP2C9: Intermediate Metabolizer)**

INFORMATIVE

Diclofenac is extensively metabolized by hydroxylation and direct glucuronidation. About 50% of diclofenac is eliminated as a 4-hydroxymetabolite, a reaction mediated by CYP2C9. Other CYP enzymes including CYP2C8, CYP2C19 and CYP3A4 are also involved in the formation of a 5-hydroxymetabolite. A substantial portion of the drug is also directly glucuronidated by UGT2B7 and UGT2B4. Individuals with decreased CYP2C9 activity (i.e. intermediate metabolizers) should be closely monitored for increased gastrointestinal adverse events when prescribed diclofenac and lower doses may be more appropriate for these patients.

**Esomeprazole**  
*Nexium***Insufficient Response to Esomeprazole (CYP2C19: Rapid Metabolizer)**

INFORMATIVE

- Helicobacter pylori eradication: increase dose by 50-100% and be alert to insufficient response.
- Other: be extra alert to insufficient response and consider dose increase of 50-100%.

**Fentanyl**  
*Actiq***Altered Response to Fentanyl (OPRM1: Altered OPRM1 Function)**

INFORMATIVE

The patient carries one copy of the OPRM1 118A>G mutation. Acute postoperative and cancer pain: the patient's genotype has been shown to be associated with reduced analgesia at standard fentanyl doses. Therefore, the patient may require higher doses of this drug. Because fentanyl has a narrow therapeutic window, it is advised to carefully titrate this drug to a tolerable dose that provides adequate analgesia with minimal side effects.

**Flurbiprofen**  
*Ansaid***Possible Sensitivity to Flurbiprofen (CYP2C9: Intermediate Metabolizer)**

INFORMATIVE

The patient may have high plasma levels of the drug. Flurbiprofen can be prescribed at standard label-recommended dosage and administration with closer monitoring for gastrointestinal side effects.

**Fluvastatin**  
*Lescol***Possible Sensitivity to Fluvastatin (CYP2C9: Intermediate Metabolizer)**

ACTIONABLE

Increased fluvastatin plasma concentrations due to reduced CYP2C9 activity may occur, resulting in myotoxicity/hepatotoxicity. Consider monitoring the patient for treatment-related adverse effects, and adjust dose as needed. Other adverse events and predisposing factors include advanced age ( $\geq 65$ ), diabetes, hypothyroidism, renal or hepatic impairments, high statin dose, CYP2C9 inhibitors, ABCG2 inhibitors, and female gender.

**PATIENT INFORMATION**

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

**SPECIMEN DETAILS**

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

**ORDERED BY**

Doctor, Doctor

**Fosphenytoin**

*Cerebyx*

**Moderate Sensitivity to Fosphenytoin (CYP2C9: Intermediate Metabolizer)****ACTIONABLE**

The genotype results indicate that the patient is a CYP2C9 substrate intermediate metabolizer. Plasma concentrations of phenytoin are likely to increase, resulting in an increased risk of mild to moderate neurological toxicity. Consider a standard loading dose, and reduce the maintenance dose by 25%. Evaluate response and serum concentrations after 7-10 days. Be alert to neurological concentration-related adverse events.

**Hydrocodone**

*Vicodin*

**Altered Response to Hydrocodone (OPRM1: Altered OPRM1 Function)****INFORMATIVE**

Acute postoperative and cancer pain: the patient's genotype has been shown to be associated with reduced analgesia and increased opioid side effects at standard or high hydrocodone doses. If the patient fails to respond to increased hydrocodone doses, an alternative opioid may be considered.

**Indomethacin**

*Indocin*

**Possible Sensitivity to Indomethacin (CYP2C9: Intermediate Metabolizer)****INFORMATIVE**

Indomethacin is metabolized mainly by O-demethylation to its inactive metabolite O-desmethylin domethacin, a reaction catalyzed by CYP2C9. At standard doses, indomethacin plasma concentrations may be higher in individuals with decreased CYP2C9 function. Although indomethacin can be prescribed at standard label recommended-dosage and administration, a closer monitoring for signs of gastrointestinal toxicity during long-term administration is recommended.

**Lansoprazole**

*Prevacid*

**Insufficient Response to Lansoprazole (CYP2C19: Rapid Metabolizer)****INFORMATIVE**

- Helicobacter pylori eradication: increase dose by 200% and be alert to insufficient response.
- Other: be extra alert to insufficient response and consider dose increase of 200%.

**Meloxicam**

*Mobic*

**Possible Sensitivity to Meloxicam (CYP2C9: Intermediate Metabolizer)****INFORMATIVE**

Meloxicam plasma concentrations may be higher in individual with decreased CYP2C9 function. A reduction in meloxicam dosage may be needed with a closer monitoring for signs of gastrointestinal toxicity during long-term administration.

**Methylphenidate**

*Ritalin*

**Decreased Response to Methylphenidate (COMT: Intermediate COMT Activity)****INFORMATIVE**

The patient's genotype result predicts a less optimal response to methylphenidate. Dosage should be individualized according to the needs and response of the patient. Therapy should be initiated in small doses, with gradual weekly increments.

**Olanzapine**

*Zyprexa*

**Non-Response to Olanzapine (CYP1A2: Normal Metabolizer - Higher Inducibility)****INFORMATIVE**

There is little evidence regarding the impact of CYP1A2 genetic variants on olanzapine response. Smokers may be at risk for non-response at standard doses. Careful monitoring is recommended during dosing adjustment. Smoking cessation may increase plasma drug levels, leading to adverse events. Therefore, therapeutic drug monitoring accompanied by dose reduction may be needed in patients who have quit smoking.

**Omeprazole**

*Prilosec*

**Insufficient Response to Omeprazole (CYP2C19: Rapid Metabolizer)****ACTIONABLE**

- Helicobacter pylori eradication: increase dose by 100-200% and be alert to insufficient response.
- Other: be extra alert to insufficient response and consider dose increase of 100-200%.

**Pantoprazole**

*Protonix*

**Insufficient Response to Pantoprazole (CYP2C19: Rapid Metabolizer)****ACTIONABLE**

- Helicobacter pylori eradication: increase dose by 400% and be alert to insufficient response.
- Other: be extra alert to insufficient response and consider dose increase of 400%.



## PATIENT INFORMATION

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

## SPECIMEN DETAILS

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

## ORDERED BY

Doctor, Doctor



**Phenytoin**  
*Dilantin*

**Moderate Sensitivity to Phenytoin (CYP2C9: Intermediate Metabolizer)**

**ACTIONABLE**

The genotype results indicate that the patient is a CYP2C9 substrate intermediate metabolizer. Plasma concentrations of phenytoin are likely to increase, resulting in an increased risk of mild to moderate neurological toxicity. Consider a standard loading dose, and reduce the maintenance dose by 25%. Evaluate response and serum concentrations after 7-10 days. Be alert to neurological concentration-related adverse events.



**Piroxicam**  
*Feldene*

**Possible Sensitivity to Piroxicam (CYP2C9: Intermediate Metabolizer)**

**INFORMATIVE**

Piroxicam plasma concentrations may be higher in individual with decreased CYP2C9 function. Although piroxicam can be prescribed at standard label-recommended dosage and administration, a closer monitoring for signs of gastrointestinal toxicity during long-term administration is recommended.



**Sertraline**  
*Zoloft*

**Possible Reduced Response to Sertraline (CYP2C19: Rapid Metabolizer)**

**INFORMATIVE**

Sertraline can be prescribed at standard label-recommended dosage and administration. If patient does not respond to recommended maintenance dosing, consider an alternative medication.



**Tetrabenazine**  
*Xenazine*

**Normal Sensitivity to Tetrabenazine (CYP2D6: Normal Metabolizer)**

**ACTIONABLE**

Individualization of dose with careful weekly titration is required. The first week's starting dose is 12.5 mg daily; second week, 25 mg (12.5 mg twice daily); then slowly titrate at weekly intervals by 12.5 mg to a tolerated dose. The **maximum daily dose in CYP2D6 normal metabolizers is 100 mg, with a maximum single dose of 37.5 mg**. If serious adverse events occur, titration should be stopped and the dose of tetrabenazine should be reduced. If the adverse event(s) do not resolve, consider withdrawal of tetrabenazine.



**Tizanidine**  
*Zanaflex*

**Possible Non-Response to Tizanidine (CYP1A2: Normal Metabolizer - Higher Inducibility)**

**INFORMATIVE**

There is little evidence regarding the impact of CYP1A2 genetic variants on tizanidine response. Smokers may be at risk for non-response and may require higher doses. There is an association between high tizanidine plasma concentrations and the risk of hypotension and excessive sedation. Therefore, careful monitoring is recommended during dosing adjustment. Smoking cessation may increase plasma drug levels, leading to excessive hypotension and sedation. Careful monitoring accompanied by dose reduction may be needed in patients who have quit smoking.



**Voriconazole**  
*Vfend*

**Non-response to Voriconazole (CYP2C19: Rapid Metabolizer)**

**ACTIONABLE**

Voriconazole plasma concentrations may be low when standard dosage is used, increasing the risk of loss of response and effectiveness. Closely monitor voriconazole plasma concentrations, and adjust the dose accordingly.



**Warfarin**  
*Coumadin*

**Mild Sensitivity to Warfarin (CYP2C9 \*1/\*3 VKORC1 -1639G>A G/G)**

**ACTIONABLE**

Initiation Therapy: a dose decrease may be required. Consider using the warfarin dose range provided in the FDA-approved label: **3-4 mg/day**. OR consider using a personalized dose calculated by a pharmacogenetic algorithm. The estimated time to reach steady state is 8-10 days.

**PATIENT INFORMATION**

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

**SPECIMEN DETAILS**

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

**ORDERED BY**

Doctor, Doctor

*Caution: It is important to note that the combination of genetic metabolizer and non-genetic factors, such as, but not limited to: body size, age, inhibition caused by interference of drugs or food, liver function, and kidney function produce the overall response to a given drug dose.*

*Methods: This specimen was analyzed for gene mutations by real-time PCR (TaqMan SNP Genotyping, Thermo Fisher) developed by Phi Life Sciences, LLC. These assays were validated following the 1988 CLIA standards. Performance characteristics were validated by Phi Life Sciences Laboratory with analytical specificity and sensitivity of >99% for detection of the variants above.*

*Lab Disclaimer: The FDA has neither cleared nor approved these assays, nor is FDA pre-market review required. These tests are used for clinical purposes and should not be regarded as investigational or for research only. Diagnosis and treatment decisions are the sole responsibility of the practitioner and does not replace the need for clinical and therapeutic drug monitoring. Hence, the interpretation and commentary are provided to the practitioner for educational purposes only and should not be taken as diagnostic or treatment recommendations. For further assistance with interpretation of these results, please contact Phi Life Sciences' Clinical Support at 888-576-5445.*

*Testing Performed By: Phi Life Sciences, LLC, CLIA No. 42D2114196, 645 Meeting St, Suite 3, Charleston, SC 29403.*

*Laboratory Director: Catherine Li, MD*

*Translational Software Disclaimer: The information presented on this report is provided as general educational health information. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Only a physician, pharmacist or other healthcare professional should advise a patient on the use of the medications prescribed.*

*The pharmacogenetic assay involves use of reporting software and genotype-phenotype associations performed by Translational Software ([www.translationalsoftware.com](http://www.translationalsoftware.com)). The software has not been evaluated by the Food and Drug Administration. The software, and the report generated by the software, is not intended to diagnose, treat, cure, or prevent any disease. A qualified designee within the lab uses Translational Software to generate and subsequently review the report. The pharmacogenetic report is one of multiple pieces of information that clinicians should consider in guiding their therapeutic choice for each patient. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to dose guidelines does not necessarily assure a successful medical outcome.*

**PATIENT INFORMATION**

**NAME:** Sample 5 S550  
**ACC #:** S550  
**DOB:** 1/1/1900  
**SEX:** M

**SPECIMEN DETAILS**

**SPECIMEN TYPE:** Buccal  
**COLLECTION DATE:** 9/7/2016  
**RECEIVED DATE:** 9/8/2016  
**REPORT DATE:** 2/6/2017

**ORDERED BY**

Doctor, Doctor

## Patient Information Card

This is a summary genetic report for your patient to share with other healthcare providers. The card can be cut out along the dashed line and carried with the patient.

**GREEN MC  
MEDS****REPORT DETAILS**

**Name:** Sample 5 S550  
**DOB:** 1/1/1900  
**ACC #:** S550

**Pharmacogenetic Test Summary**

COMT	Val158Met AG	Intermediate COMT Activity
CYP1A2	*1A/*1F	Normal Metabolizer - Higher Inducibility
CYP2C19	*1/*17	Rapid Metabolizer
CYP2C9	*1/*3	Intermediate Metabolizer
CYP2D6	*1/*3	Normal Metabolizer
CYP3A4	*1/*1	Normal Metabolizer
CYP3A5	*3/*3	Poor Metabolizer
Factor II	20210G>A GG	Normal Thrombosis Risk
Factor V Leiden	1691G>A GG	Normal Thrombosis Risk
LPA	rs10455872 A/A	Wild-type for rs10455872
LPA	rs3798220 T/T	Wild-type for rs3798220
MTHFR	677C>T CC	Normal MTHFR Activity
MTHFR	1298A>C AC	Reduced MTHFR Activity
OPRM1	A118G AG	Altered OPRM1 Function
SLC6A4	463T>G A/A	Homozygous for A Allele
SLCO1B1	521T>C TT	Normal Function
VKORC1	-1639G>A G/G	Low Warfarin Sensitivity